224 related articles for article (PubMed ID: 31450846)
1. Aberrant Methylation Status of Tumour Suppressor Genes in Ovarian Cancer Tissue and Paired Plasma Samples.
Dvorská D; Braný D; Nagy B; Grendár M; Poka R; Soltész B; Jagelková M; Zelinová K; Lasabová Z; Zubor P; Danková Z
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450846
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation of MGMT, CDH1, RAR-beta and SYK tumour suppressor genes in granulosa cell tumours (GCTs) of ovarian origin.
Dhillon VS; Young AR; Husain SA; Aslam M
Br J Cancer; 2004 Feb; 90(4):874-81. PubMed ID: 14970867
[TBL] [Abstract][Full Text] [Related]
3. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
[TBL] [Abstract][Full Text] [Related]
4. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer.
Singh A; Gupta S; Badarukhiya JA; Sachan M
Int J Cancer; 2020 Sep; 147(6):1740-1752. PubMed ID: 32191343
[TBL] [Abstract][Full Text] [Related]
5. An epigenetic marker panel for screening and prognostic prediction of ovarian cancer.
Su HY; Lai HC; Lin YW; Chou YC; Liu CY; Yu MH
Int J Cancer; 2009 Jan; 124(2):387-93. PubMed ID: 18942711
[TBL] [Abstract][Full Text] [Related]
6. Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer.
Abou-Zeid AA; Azzam AZ; Kamel NA
Scand J Clin Lab Invest; 2011 Nov; 71(7):542-7. PubMed ID: 21728901
[TBL] [Abstract][Full Text] [Related]
7. Relationship between promoter methylation & tissue expression of MGMT gene in ovarian cancer.
Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
Indian J Med Res; 2014 Nov; 140(5):616-23. PubMed ID: 25579142
[TBL] [Abstract][Full Text] [Related]
8. Methylomic Analysis of Ovarian Cancers Identifies Tumor-Specific Alterations Readily Detectable in Early Precursor Lesions.
Pisanic TR; Cope LM; Lin SF; Yen TT; Athamanolap P; Asaka R; Nakayama K; Fader AN; Wang TH; Shih IM; Wang TL
Clin Cancer Res; 2018 Dec; 24(24):6536-6547. PubMed ID: 30108103
[TBL] [Abstract][Full Text] [Related]
9. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
10. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer.
Topaloglu O; Hoque MO; Tokumaru Y; Lee J; Ratovitski E; Sidransky D; Moon CS
Clin Cancer Res; 2004 Apr; 10(7):2284-8. PubMed ID: 15073103
[TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Kikuchi R; Tsuda H; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
Cancer Res; 2007 Aug; 67(15):7095-105. PubMed ID: 17671176
[TBL] [Abstract][Full Text] [Related]
12. Promoter methylation in the PTCH gene in cervical epithelial cancer and ovarian cancer tissue as studied by eight novel Pyrosequencing® assays.
Löf-Öhlin ZM; Levanat S; Sabol M; Sorbe B; Nilsson TK
Int J Oncol; 2011 Mar; 38(3):685-92. PubMed ID: 21206974
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843
[TBL] [Abstract][Full Text] [Related]
14. Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis.
Loginov VI; Pronina IV; Burdennyy AM; Filippova EA; Kazubskaya TP; Kushlinsky DN; Utkin DO; Khodyrev DS; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2018 Jul; 662():28-36. PubMed ID: 29631007
[TBL] [Abstract][Full Text] [Related]
15. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir.
Asiaf A; Ahmad ST; Aziz SA; Malik AA; Rasool Z; Masood A; Zargar MA
Asian Pac J Cancer Prev; 2014; 15(15):6397-403. PubMed ID: 25124632
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic silencing of the LDOC1 tumor suppressor gene in ovarian cancer cells.
Buchholtz ML; Brüning A; Mylonas I; Jückstock J
Arch Gynecol Obstet; 2014 Jul; 290(1):149-54. PubMed ID: 24554348
[TBL] [Abstract][Full Text] [Related]
17. A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.
Gallardo-Gómez M; Moran S; Páez de la Cadena M; Martínez-Zorzano VS; Rodríguez-Berrocal FJ; Rodríguez-Girondo M; Esteller M; Cubiella J; Bujanda L; Castells A; Balaguer F; Jover R; De Chiara L
Clin Epigenetics; 2018; 10():53. PubMed ID: 29686738
[TBL] [Abstract][Full Text] [Related]
18. Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer.
Wu Y; Zhang X; Lin L; Ma XP; Ma YC; Liu PS
Asian Pac J Cancer Prev; 2014; 15(3):1171-6. PubMed ID: 24606436
[TBL] [Abstract][Full Text] [Related]
19. The association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis.
Wang Q; Wang B; Zhang YM; Wang W
J Ovarian Res; 2016 Apr; 9():23. PubMed ID: 27067410
[TBL] [Abstract][Full Text] [Related]
20. [Methylation of selected tumor-supressor genes in benign and malignant ovarian tumors].
Cul'bová M; Lasabová Z; Stanclová A; Tilandyová P; Zúbor P; Fiolka R; Danko J; Visnovský J
Ceska Gynekol; 2011 Sep; 76(4):274-9. PubMed ID: 22026068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
